RHYTHM PHARMACEUTICALS, INC. Net Fee Amt
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Net Fee Amt of $207.15 as of 2026-05-04, per its S-8 filed 2026-05-05.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-05
- 2026-05-04: Net Fee Amt $207.15.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-04 | $207.15 S-8 · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |